ESC Premium Access

PCSK9 inhibitors post Fourier: who should be treated and when?

Congress Presentation

About the speaker

Professor Steven E Nissen

Cleveland Clinic Hospital, Cleveland (United States of America)
14 presentations
0 follower

3 more presentations in this session

siRNA therapy: the dawn of a new agent in cholesterol lowering?

Speaker: Doctor L. Cho (Cleveland, US)


Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?

Speaker: Professor E. Stroes (Amsterdam, NL)


Current state of knowledge on the mechanism of action of bempedoic acid and its potential for LDL-C lowering and CV risk reduction.

Speaker: Professor S. Nicholls (Melbourne, AU)


Access the full session

Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Speakers: Professor S. Nissen, Doctor L. Cho, Professor E. Stroes, Professor S. Nicholls

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb